



# Acute Canine Pancreatitis - Diagnosis and Treatment

Presenters: Yvonne McGrotty

European & RCVS Specialist in SA  
Internal Medicine

March 2025

**IDEXX**

## Disclosures:

Part-time employee of IDEXX, UK

Part-time employee of AniCura, France




# Pancreatic Enzymes

- + Secreted & stored as precursor molecules
  - + Zymogens
- + Activation of trypsinogen occurs in duodenum
  - + Enterokinase
  - + Trypsinogen → Trypsin
- + Trypsin activates other zymogens
- + Prevents autodigestion



# Pancreatitis

- + Intraductal/intracellular activation of pancreatic enzymes
- + Destruction of pancreatic tissue
- + Oedema
- + Haemorrhage
- + Necrosis



# Two primary types of pancreatitis...

**Acute**

**Chronic**



## **Acute Pancreatitis**

- Neutrophilic inflammation
- Oedema and necrosis
- Peripancreatic fat saponification
- REVERSIBLE
  
- May lead to chronic pancreatitis
  - Acute necrotizing (cell death) pancreatitis is a life-threatening condition

## **Chronic Pancreatitis**

- Lymphocytic inflammation
- Permanent progressive fibrosis
- Acinar atrophy
- IRREVERSIBLE
  
- Flare-ups may occur, resulting in acute pancreatitis
  - Often manageable with close monitoring and dietary discretion

DeCock, Forman et al. 2007

# Prevalence of Acute Pancreatitis

- + In 40 dogs with acute vomiting
  - + 35.7% for primary AP
  - + 64.3% for secondary AP
    - + GI foreign body
    - + Renal disorders
    - + Hepatic tumours
- + Common
- + Probably underdiagnosed
- + Diagnosis is challenging



Abhilaasha, C.M., Chandrasekaran, D., Kavitha, S. and Vairamuthu, S. (2020). Prevalence of acute pancreatitis in dogs. *J. Anim. Res.*, 10(3): 453-458

# Aetiology #1

- + Most cases idiopathic
  - + Risk factors in dogs not very clear
- + Diet?
- + Drugs
  - + (L-asp, phenobarb, potassium bromide, azathioprine, meglumine antimonate)
- + Toxins
  - + Organophosphates
- + Endocrine disease
  - + HAC, DM, hypoT4
  - + Maybe due to high trigs
  - + Glucose toxicity may play a part in DM



## Aetiology #2

- Hypertriglyceridaemia
  - XS trig broken down to FFA by pancreatic lipase
- Breed disposition
  - Schnauzer, Cavalier, Poodle, Cocker
  - SPINK gene mutation in Schnauzer
- Hypercalcaemia
- Miscellaneous
  - Ischaemia





# Presenting Signs

- + Dehydration
- + Abdominal pain
- + Fever
- + Jaundice
- + Vomiting
- + Weakness
- + Abdominal pain
- + Diarrhoea
- + Haematemesis



> [J Am Vet Med Assoc. 1998 Sep 1;213\(5\):665-70.](#)

**Clinical, clinicopathologic, radiographic, and ultrasonographic abnormalities in dogs with fatal acute pancreatitis: 70 cases (1986–1995)**

[R S Hess](#)<sup>1</sup>, [H M Saunders](#), [T J Van Winkle](#), [F S Shofer](#), [R J Washabau](#)


# Complications of Pancreatitis

## + Local

- + Pancreatic necrosis
- + Peripancreatic fluid
- + EHBDO
- + Thromboembolic disease
- + GI stasis

## + Systemic

- + Coagulopathy/DIC
- + Acute kidney injury
- + Aspiration pneumonia
- + Transient hyperglycaemia
- + Myocarditis
- + SIRS/MODS



Non-specific Clin Path  
Changes in Acute  
Pancreatitis



# Haematology

+ Neutrophilia (+/- left shift)

+ Mild non regenerative anaemia

+ Mild thrombocytopenia

■ ■ ■	∞	RBC	5.91	5.65 - 8.87 x10 <sup>12</sup> /L	
■ ■ ■	∞	<b>Haematocrit</b>	<b>0.369</b>	0.373 - 0.617 L/L	
■ ■ ■	∞	<b>Haemoglobin</b>	<b>123</b>	131 - 205 g/L	
■ ■ ■	∞	MCV	62.4	61.6 - 73.5 fL	
■ ■ ■	∞	<b>MCH</b>	<b>20.8</b>	21.2 - 25.9 pg	
■ ■ ■	∞	MCHC	333	320 - 379 g/L	
■ ■ ■	∞	RDW	17.8	13.6 - 21.7 %	
■ ■ ■		% Reticulocytes	1.8	%	
■ ■ ■	∞	Reticulocytes	104.0	10.0 - 110.0 K/μL	
■ ■ ■	∞	Reticulocyte Haemoglobin	24.1	22.3 - 29.6 pg	
■ ■ ■	∞	<b>WBC</b>	<b>19.90</b>	5.05 - 16.76 x10 <sup>9</sup> /L	
■ ■ ■		% Neutrophils	79.5	%	
■ ■ ■		% Lymphocytes	5.4	%	
■ ■ ■		% Monocytes	11.3	%	
■ ■ ■		% Eosinophils	3.6	%	
■ ■ ■		% Basophils	0.2	%	
■ ■ ■	∞	<b>Neutrophils</b>	<b>15.84</b>	2.95 - 11.64 x10 <sup>9</sup> /L	
■ ■ ■	∞	Lymphocytes	1.07	1.05 - 5.10 x10 <sup>9</sup> /L	
■ ■ ■	∞	<b>Monocytes</b>	<b>2.25</b>	0.16 - 1.12 x10 <sup>9</sup> /L	
■ ■ ■	∞	Eosinophils	0.71	0.06 - 1.23 x10 <sup>9</sup> /L	
■ ■ ■	∞	Basophils	0.03	0.00 - 0.10 x10 <sup>9</sup> /L	

# Biochemistry

- + Increased liver enzymes
- + Increased bilirubin
- + Increased triglycerides/cholesterol
- + Hypoalbuminaemia
- + Hyperglycaemia/hypoglycaemia
- + Azotaemia (prerenal vs renal)
- + Hypokalaemia
  
- + Hypertriglyceridemia
- + Hypercholesterolaemia
- + Hyperlactataemia

Glucose	5.7	3.6 - 7.0 mmol/L	
IDEXX SDMA	9	1 - 14 µg/dL	
Creatinine	76.0	44.0 - 133.0 µmol/L	
Urea	3.4	3.1 - 10.1 mmol/L	
IDEXX Cystatin B (Urine)	74	0 - 99 ng/mL	
Phosphorus	0.87	0.80 - 1.60 mmol/L	
Calcium	2.43	2.36 - 2.84 mmol/L	
Sodium	147.0	135.0 - 155.0 mmol/L	
Potassium	4.33	3.60 - 5.60 mmol/L	
Na: K Ratio	33.95	28.80 - 40.00	
Chloride	111.1	100.0 - 116.0 mmol/L	
Total Protein	61.0	54.9 - 75.3 g/L	
<b>Albumin</b>	<b>25.2</b>	26.3 - 38.2 g/L	
Globulin	35.8	23.4 - 42.2 g/L	
Albumin: Globulin Ratio	0.70	0.70 - 1.40	
<b>ALT</b>	<b>546.9</b>	19.8 - 124.0 U/L	
<b>ALP</b>	<b>4,027.0</b>	0.0 - 130.0 U/L	
<b>Bilirubin - Total</b>	<b>254.5</b>	<= 5.1 µmol/L	
<b>Cholesterol</b>	<b>&gt;18.00</b>	3.20 - 6.20 mmol/L	

# C Reactive Protein (CRP)


- + Increased in 90% of dogs with AP
- + May be used to monitor response to treatment
- + CRP for non-survivors significantly higher than for survivors
- + Persistent elevation associate with poor prognosis

> [J Vet Intern Med. 2021 Sep;35\(5\):2187-2195. doi: 10.1111/jvim.16218. Epub 2021 Jul 11.](#)

## **Serum concentrations of canine pancreatic lipase immunoreactivity and C-reactive protein for monitoring disease progression in dogs with acute pancreatitis**

[Kirstin M Keany](#)<sup>1</sup>, [Geoffrey T Fosgate](#)<sup>2</sup>, [Sean M Perry](#)<sup>3</sup>, [Shannon T Stroup](#)<sup>1</sup>, [Joerg M Steiner](#)<sup>4</sup>


## **Prognostic value of C-reactive protein in dogs with elevated serum pancreatic lipase immunoreactivity concentrations**

[Sydney M. Oberholtzer](#) DVM , [Audrey K. Cook](#) BVM&S, MSc Vet Ed, DACVIM, DECVIM, DABVP, [Robynne Gomez](#) MS, and [Jörg M. Steiner](#) MedVet, DrMedVet, PhD, DACVIM, DECVIM

DOI: <https://doi.org/10.2460/javma.23.09.0533>

Volume/Issue: Volume 262: Issue 3

Received: 26 Sep 2023 | Accepted: 03 Nov 2023 | Online Publication Date: 01 Dec 2023

► [J Vet Med Sci. 2016 Sep 23;79\(1\):35–40. doi: 10.1292/jvms.16-0009](#) 

## **Assessment of severity and changes in C-reactive protein concentration and various biomarkers in dogs with pancreatitis**


[Toru SATO](#)<sup>1</sup>, [Koichi OHNO](#)<sup>1,\*</sup>, [Takashi TAMAMOTO](#)<sup>1</sup>, [Mariko OISHI](#)<sup>1</sup>, [Hideyuki KANEMOTO](#)<sup>1</sup>, [Kenjiro FUKUSHIMA](#)<sup>1</sup>,  
[Yuko GOTO-KOSHINO](#)<sup>1</sup>, [Masashi TAKAHASHI](#)<sup>1</sup>, [Hajime TSUJIMOTO](#)<sup>1</sup>

# Diagnosis of Acute Pancreatitis



# Diagnosis of Acute Pancreatitis- Multimodal

- + Signalment
- + Clinical signs
- + Supportive blood results
- + Pancreatic lipases
- + Supportive imaging
- + Pancreatic FNA
- + Pancreatic biopsy?





## Specific Diagnostics for Acute Pancreatitis



# Canine Pancreatic Lipases

- + Immunological Assays (PLI)
  - + Spec cPL<sup>®</sup> (quantitative)
  - + SNAP cPL<sup>®</sup> (semi quantitative)
  
- + Catalytic Methods
  - + Standard lipases 1,2 Diglyceride
  - + DGGR lipases
  
- + Most sensitive and specific marker for pancreatitis



# Spec cPL<sup>®</sup>

- + Most sensitive and specific marker for diagnosis of pancreatitis
- + Uses 2 sets of monoclonal antibodies against canine pancreatic lipase (ELISA)
- + Doesn't detect extra pancreatic lipases
- + Validated in dogs (and fPL incats)
- + Not affected by icterus, haemolysis or lipaemia

0-200 ug/L pancreatitis unlikely  
200-400 ug/L pancreatitis possible  
> 400 ug/L pancreatitis probable

	Cut-off 200	400
<b>Sensitivity</b>	43-94%	21-90%
<b>Specificity</b>	66-95%	74-100%

*J Vet Intern Med* 2015

### Clinical Utility of Diagnostic Laboratory Tests in Dogs with Acute Pancreatitis: A Retrospective Investigation in a Primary Care Hospital

M. Yuki, T. Hirano, N. Nagata, S. Kitano, K. Imataka, R. Tawada, R. Shimada, and M. Ogawa

# Lateral Flow Immunoassay- SNAP cPL<sup>®</sup>

- + Very good agreement with Spec cPL<sup>®</sup>
  - + 94-97.4% agreement
  
- + 97.5% agreement for normal results
- + 90% agreement for abnormal results
  
- + Please use conjugate with correct lot number!!



# Lipase assays: aren't they all the same?



## Activity assays

- + Chemical reagent that mimics fat
- + Measure amount of reagent breakdown over a specific time
- + Various substrates available
- + Specificity for pancreatic lipase varies among available assays
- + Traditionally measured in U/L
- + Examples include the Catalyst<sup>®</sup> Pancreatic Lipase Test and the assay used at IDEXX Reference Laboratories



## Immunoassays

- + Specific antibodies against canine or feline pancreatic lipase
- + Measures the amount of antibody binding to pancreatic lipase
- + High specificity for pancreatic lipase
- + Measured in  $\mu\text{g/L}$
- + Examples include the Spec cPL<sup>®</sup>, Spec fPL<sup>®</sup>, SNAP<sup>®</sup> cPL<sup>™</sup>, and SNAP<sup>®</sup> fPL<sup>™</sup> tests

# Catalyst PL = DGGR Lipase

- + More specific for pancreas than general lipase
  - + Substrate hydrolysed by pancreatic lipase
- + Heparin or serum
- + Correlates well with Spec cPL<sup>®</sup>
- + Moderate to severe haemolysis may impact results
- + Icterus or lipaemia don't affect results
- + Low in most cases of EPI



**Chemistry** 24/02/2025 09:15

**Catalyst Pancreatic Lipase** a **983** 0 - 200 U/L


a. **Pancreatic Lipase:**  
Pancreatic lipase is consistent with pancreatitis ( $\geq 400$  U/L). If clinical signs are present, treat appropriately, and investigate for risk factors and concurrent diseases including gastroenteritis or foreign body. Monitor Catalyst Pancreatic Lipase to assess response to treatment. If clinical signs are not present, consider additional diagnostics, instruct owner to monitor closely and recheck Catalyst Pancreatic Lipase in 2-3 weeks.

# Catalyst Pancreatic Lipase

- + Validated range in dogs
  - + 30-2000 U/L
- + One test validated for both dogs and cats.
- + Accurate and specific quantitative results that align with the IDEXX Reference Laboratories Spec cPL<sup>®</sup> and Spec fPL<sup>®</sup> tests.



Perform the Catalyst® Pancreatic Lipase Test if clinical signs<sup>†</sup> of pancreatitis are present or if lipase on chem 17 profile is substantially elevated\*






# Imaging for Acute Pancreatitis



# Ultrasound

- + Large, hypoechoic pancreas
- + Hyperechoic peripancreatic fat
- + Dilation of ducts
  
- + Better for diagnosing acute necrotising pancreatitis
  
- + US resolution can lag behind clinical improvement
  
- + US evidence of pancreatitis in absence of other evidence should be interpreted with caution



# Pancreatic FNA

- + Can be useful to diagnose AP
  - + Diagnostic in 74% cases
  - + Neutrophils and pancreatic acinar cells
- + Safe
- + Correlates with histology in 91%
- + Localised lesions may be missed



## Cytologic findings and diagnostic yield in 92 dogs undergoing fine-needle aspiration of the pancreas

Journal of Veterinary Diagnostic Investigation  
2015, Vol. 27(2) 236-240  
© 2015 The Author(s)  
Reprints and permissions:  
sagepub.com/journalsPermissions.nav  
DOI: 10.1177/1040638715574862  
jvdi.sagepub.com

Amy P. Cordner, Leslie C. Sharkey,<sup>1</sup> P. Jane Armstrong, Kaitlyn D. McAteer

# Pancreatic Fluid


- + Not frequently identified
- + Generally considered safe to aspirate
  - + Sterile vs septic
- + Very few cases found to be septic



Talbot CT, Cheung R, Holmes EJ, Cook SD. Medical and surgical management of pancreatic fluid accumulations in dogs: A retrospective study of 15 cases. *J Vet Intern Med.* 2022; 36(3): 919-926. doi:[10.1111/jvim.16411](https://doi.org/10.1111/jvim.16411)

# Pancreatic Biopsy

- + Gold standard for diagnosis
- + May not be a good anaesthetic candidate
- + May be patchy distribution
  - + Multiple biopsies
- + Doesn't change treatment



# Management of Acute Canine Pancreatitis



# Fluid Therapy

- + Balanced isotonic solution
  - + Lactated Ringers (Hartmann's)
- + Individualised approach
- + Potassium supplementation
- + Fluid overload detrimental!
  - + Interstitial oedema
  - + Third spacing
  - + Worsening hypoalbuminaemia



# How Much Fluid?- Daily Fluid Requirements

+  $30 \times \text{BW kg} + 70 = \text{ml/day}$

+  $132 \times \text{BW kg}^{0.75}$

+ For cats use  $80 \times \text{BW kg}^{0.75}$

+ 40-60ml/kg/day



Pardo M, Spencer E, Odunayo A, Ramirez ML, Rudloff E, Shafford H, Weil A, Wolff E. 2024 AAHA Fluid Therapy Guidelines for Dogs and Cats. J Am Anim Hosp Assoc. 2024 Jul 1;60(4):131-163.



# Calculating Fluid Requirements

+ Fluid **deficit** = % dehydration x Bodyweight (kg) x 1000

+ Add **maintenance** fluids = 40-60mls/kg/day

+ Add **ongoing losses** (vomiting, diarrhoea, polyuria)

+ Total requirements = **deficit** + **maintenance** + **ongoing losses**

# Example

+ 30kg dog which is 10% dehydrated  
+ tachycardia, dry mm, prolonged CRT

+ Fluid deficit = 3000mls ( $0.10 \times 30 \times 1000$ )

+ Maintenance = 1500mls ( $50 \times 30$ )

+ Total fluid requirement for 24 hours

= **4500mls/day!!!!** + ongoing losses = 187ml/h



# How Long?- Avoid Fluid Overload with ROSE

## + Resuscitation

- + Rapid administration over a few mins
- + Fluid boluses of balanced crystalloids

## + Optimisation

- + Maintain effective circulation
- + Lasts a few hours

## + Stabilisation

- + Maintenance fluid therapy
- + Lasts a few days
- + Weigh patient twice daily

## + Evacuation

- + Patient eliminates excess fluids via the kidneys
- + May lead to oedema if vascular damage present



# Pain Management

## Opioids

- + Methadone
- + Fentanyl
- + Buprenorphine

## + NDMA antagonists

- + Ketamine

## + CRIs

- + Lidocaine CRI
- + MLK/FLK

## + Paracetamol

## + NSAIDs???- no



# Nutritional Support

- + NPO NOT recommended
- + Early enteral nutrition recommended
  
- + Highly digestible
- + Low fat (<20g fat/1000kcal)
  
- + Feeding tubes
  
- + Appetite stimulants
  - + Mirtazapine (0.5-1.5mg/kg q24h)
  - + Capromorelin (3mg/kg q24h)



Zollers B, Wofford JA, Heinen E, Huebner M, Rhodes L. A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite. J Vet Intern Med. 2016 Nov;30(6):1851-1857.

# Anti-emetics

## + Maropitant

- + Selective NK-1 receptor antagonist
- + Blocks substance P
- + Acts on central & peripheral pathways

## + Ondansetron

- + 5-HT<sub>3</sub> antagonist
- + Anti-emetic & anti- nausea

## + Metoclopramide?

- + Dopamine D<sub>2</sub> antagonist
- + Weak antiemetic
- + Prokinetic in upper GIT
- + Not really recommended in AP



Lorenzutti AM, Martín-Flores M, Litterio NJ, Himelfarb MA, Invaldi SH, Zarazaga MP. A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs. *Can Vet J.* 2017 Jan;58(1):35-38. PMID: 28042152; PMCID: PMC5157735.

# Other drugs?

- + Anti-thrombotics (severe cases)
  - + Necrotising pancreatitis & signs of hypercoagulability
- + Omeprazole
  - + No clear indication
  - + Increased risk of aspiration pneumonia if aspiration occurs
  - + Only if melaena/haematemesis
- + Corticosteroids
  - + Not currently recommended
  - + Pro-coagulant
- + Antibiotics
  - + Not recommended!
  - + Only if pyrexia, left shift, melaena



I have pledged to be an  
**ANTIBIOTIC GUARDIAN**  
My actions protect antibiotics

Become an Antibiotic Guardian. Join me at [antibioticguardian.com](https://antibioticguardian.com)

UK Health Security Agency | HSC Health and Social Care | Keep Antibiotics Working | NHS SCOTLAND | GIG Cymru NHS Wales Iechyd Cyhoeddus Cymru Public Health Wales

# New Horizons? -Fuzapladib

- + Leukocyte function antigen inhibitor (LFA-1)
- + Prevents extravasation of neutrophils into pancreas
- + Injectable drug given IV daily for 3 days
- + Not yet available in Europe

Multicenter Study > J Vet Intern Med. 2023 Nov-Dec;37(6):2084-2092. doi: 10.1111/jvim.16897.  
Epub 2023 Oct 9.

## Fuzapladib in a randomized controlled multicenter masked study in dogs with presumptive acute onset pancreatitis

Joerg M Steiner<sup>1</sup>, Chantal Lainesse<sup>2</sup>, Yuya Noshiro<sup>3</sup>, Yumiko Domen<sup>4</sup>, Heather Sedlacek<sup>5</sup>, Stephen E Bienhoff<sup>5</sup>, Kelly P Doucette<sup>6</sup>, David L Bledsoe<sup>6</sup>, Hiroshi Shikama<sup>7</sup>





# Prognosis

- + Depends on severity of disease
- + High morbidity and mortality in severe cases
  - + Mortality from 20-42%
- + Higher mortality with comorbidities or complications
  - + Pancreatic fluid accumulation
  - + Diabetes mellitus
  - + Kidney disease
  - + Coagulopathy
  - + SIRS



Cook AK, Breitschwerdt EB, Levine JF, Bunch SE, Linn LO. Risk factors associated with acute pancreatitis in dogs: 101 cases (1985-1990). J Am Vet Med Assoc. 1993 Sep 1;203(5):673-9.

Any Questions?

